Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of CYD Dengue Vaccine and Cervarix in Healthy Females
NCT02979535Phase 3Completed
- Sponsor
- Sanofi
- Start
- Nov 2016
- Primary completion
- Mar 2019
- Modality
- Live Attenuated Vaccines, Recombinant Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Cyd dengue virus serotype 1 live (attenuated) antigen in dengue fever (2 arms), sponsored by Sanofi. Primary endpoints: Geometric Mean Titers Against Each Cervarix Human Papillomavirus Antigen and Geometric Mean Titers Against Each Dengue Virus Serotype. Started Nov 2016; status: completed.
02
Drugs
Cyd dengue virus serotype 1 live (attenuated) antigen
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT02979535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02979535.